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ABSTRACT

Traumatic brain injury (TBI) is the most frequent cause of death in children and
young adults in the United States. Besides emergency neurosurgical procedures, there
are few medical treatment options to improve recovery in people who have experienced
a TBI. Management of patients who survive TBI is complicated by both central nervous
system and peripheral systemic effects. The pathophysiology of systemic inflammation
and coagulopathy following TBI has been attributed to trauma-induced endothelial cell
dysfunction; however, there is little knowledge of the mechanisms by which trauma
might impact the functions of the vascular endothelium at sites remote from the injury.
The endothelium lining these small vessels normally produces nitric oxide (NO),
arachidonic acid metabolites, and endothelial-dependent hyperpolarizing factors to relax
the surrounding vascular smooth muscle. For this research study we investigated the
effects of fluid-percussion-induced TBI on endothelial-dependent vasodilatory functions
in a remote tissue bed (the mesenteric circulation) 24 hours after injury. We hypothesized
that TBI causes changes in the mesenteric artery endothelium that result in a loss of
endothelial-dependent vasodilation. We found that vasodilations induced by the
muscarinic-receptor agonist, acetylcholine, are attenuated following TBI. While the
endothelial-derived hyperpolarizing component of vasodilation was preserved, the NO
component was severely impaired. Therefore, we tested whether the loss of NO
component was due to a decrease in bioavailablity of the NO synthase (NOS) cofactor
BH4, the NOS substrate L-arginine, or to changes in expression/activity of the enzyme
arginase, which competes with NOS for L-arginine. We found that supplementation of
L-arginine and inhibition of the enzyme arginase rescues endothelial-dependent
vasodilations in TBI arteries. This study demonstrates that there are pathological
systemic effects outside the point of injury following TBI leading to a dysfunctional
endothelial vasodilatory pathway. These data provide insight into the pathophysiology
of endothelial dysfunction after trauma and may lead to new potential targets for drug
therapy.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

1.1. Epidemiology
Traumatic brain injury (TBI) represents the leading cause of morbidity and
mortality worldwide in individuals under the age of 45, and is increasingly recognized as
a major health care problem in the United States [73]. According to the US Department of
Health and Human Services, there are approximately 1.7 million TBIs each year, resulting
in 52,000 deaths, 275,000 hospitalizations and 1,365,000 emergency department visits
[33]. The reported data may underestimate the true amount of TBI-related injuries due to
possible misdiagnosis, unreported outpatient treatment, and patients who do not seek health
care after injury. Despite increased helmet use and safety measures, recent data indicate
increasing emergency department visits for TBI in the US; this may be due in part to
increased awareness, exposure, and diagnostics [76]. People who survive brain injury can
suffer from long-term effects diminishing their productivity and overall quality of life. It
has been estimated that more than 124,000 additional people each year will suffer from
significant long-term disabilities after severe brain trauma [117].

Some individuals

develop dementia and chronic traumatic encephalopathy from more mild, often repetitive,
concussions [117]. Long-term effects can also arise from TBI and can include pathological
manifestations such as seizures, epilepsy, neurodegeneration and Alzheimer’s disease [32].
Thus, the total cost to society and to our health care system from TBI is enormous.
The most common mechanism of injury resulting in a TBI is through a fall, but this
is most prevalent in older adults [33]. Motor vehicle accidents, almost as common, account
1

for the largest proportion of TBI-related deaths [33]. Sports and recreational activities are
also a major cause of TBI. Sports related mild TBI does not always involve a loss of
consciousness and can go unrecognized and uncounted. It has been estimated that 1.6 to
3.6 million sports related TBI occur every year and can cause long term cognitive problems
[70]. Another major risk factor for TBI is military combat, particularly in recent times with
warriors wearing Kevlar helmets and sustaining blast injuries from improvised explosives.
In a survey of U.S. Army infantry soldiers, 15.2% reported blast injuries in which they
suffered either a loss of consciousness or altered mental status during deployment; of note
these individuals were at substantially higher risk for post-traumatic stress disorder [50].
Children between the ages of 0-4 and adults over the age of 75 years have the
highest rate of TBIs [10]. Males appear to have more TBIs, with a higher rate of
hospitalization, emergency visits and deaths related to TBI than the female population [33]
who appear to be protected by the hormone progesterone [2,27].

1.2. Clinical classification
A TBI is defined as an injury to the brain, caused either by blunt trauma, penetrating
trauma, rapid motion or blast injury to the cranium which leads to a disruption of regular
cerebral function [96]. TBI can range from mild to severe, and while there are multiple
ways to classify TBIs, they all suffer from limitations. Currently, the most common scoring
system for severity of brain injury is the Glasgow Coma Scale (GCS), which classifies
injuries as mild, moderate or severe, by scoring the level of consciousness at first medical
contact after a head trauma [73]. The score is the sum of three physical exam findings:
2

eye, motor and verbal reflexes. A GCS score of 13, 14 or 15 defines “mild TBI”, typically
a brief change in mental status or consciousness, and interchangeably called “concussion”.
“Moderate TBI”, with GCS score of 9-12 [73], predicts a higher probability of permanent
disability. GCS scores of 3-8 define “severe TBI”, typically presenting with an extended
period of unconsciousness and coma, and predict a high risk of death [73]. Other similar
scoring systems based on clinical findings include the injury severity score, Brussels coma
scale, Grady Coma Scale, and Innsbruck coma scale.
After neuroimaging (typically, non-contrast computed tomography scan of the
brain), brain trauma is described clinically by anatomic location and pattern of injury.
Severe TBI can be heterogenenous, and there are at least 6 different patterns of injury that
can result in GCS < 8 [96]. Patterns include subdural hematoma, cerebral contusion, or
subarachnoid, intraparenchymal, or intraventricular hemorrhage, with or without brain
edema or “midline shift” [96]. Diffuse axonal injury without bleeding can also result in
coma and death, but can only be seen on magnetic resonance imaging (MRI). Severity
classifications can also be made according to the patho-anatomic classification of injury,
describing the location, anatomical features of injury and size of lesion. The Marshall Score
is based on CT scan results, and can be used to predict the risk of increased intracranial
pressure and outcome in adults [74].
There are several clinical tools that are used to measure clinical outcomes in
patients who survive TBI. The Glasgow outcomes score (extended), and disability rating
scale, have been used to describe clinical outcomes or neurologic injury severity [74].
Unfortunately, there are currently no diagnostic tools that can accurately predict outcomes
3

after a TBI. Current methods of classifying TBI do not take into account the subsequent
secondary systemic effects that may occur during the recovery period following TBI.

1.3 Pathophysiology
TBI is a heterogeneous disease that has variable pathophysiological outcomes
which compound the issue of diagnosis and treatment. As described in the section above,
injury can be classified by the physical mechanism of impact (blunt, penetrating, rotational,
or blast), pathoanatomic features, and clinical findings. Primary injury to brain structures
by any mechanism happens immediately and is a direct result of mechanical trauma [73].
Tissue damage may include shearing of white matter, focal bleeding, swelling within gray
matter, hematomas, microporation of membranes, and vascular injury [60,74].

The

physical mechanism of impact can predict the type and severity of the tissue injury.
Different mechanisms such as direct impact, rapid acceleration or deceleration, penetration
(gunshot) or blast waves from an explosion produce typical patterns of tissue damage [74].
Diffuse axonal injury, with multiple lesions or shearing of white matter tracts, occurs most
commonly through an acceleration/deceleration mechanism [52].
Secondary insults after TBI can arise hours to days later and may involve the release
of neurotransmitters (glutamate), ion channel leakage, reactive oxygen species (ROS)
production, blood brain barrier (BBB) breakdown, edema and increased intracranial
pressure (ICP) [31,73,74,82]. Progression of intracranial hemorrhage and progressive
edema are the most common secondary insult following an initial traumatic injury [96].
Common secondary changes that occur to the brain after TBI also include progressive
4

white matter changes (after axonal injury), reactive gliosis, and degeneration of neural
tissue and Tau protein accumulation, which has been associated with chronic traumatic
encephalopathy [13]. The most common form of TBI is diffuse axonal injury where there
are multiple lesions or shearing of white matter tracts and occurs most commonly through
acceleration/deceleration impact such as a car accident [52]. Although the primary brain
injury is untreatable from the standpoint of the clinician, secondary effects of TBI may be
avoidable and are of major interest to researchers and health care providers.
The cerebral circulation appears highly vulnerable to secondary pathophysiological
effects after TBI. One of the most important physiological properties of the cerebral
circulation is cerebral autoregulation which is the mechanism that maintains cerebral blood
flow (CBF) constant despite changes in cerebral perfusion pressure [91].

Cerebral

autoregulation is maintained by myogenic, neurogenic, and metabolic mechanisms. The
myogenic component is defined as the inherent mechanism of vascular smooth muscle cells
(VSMCs) to constrict or dilate in response to changes in intramural pressure [91]. Multiple
studies have demonstrated that more than 50% of TBI patients have shown an impairment
in autoregulation [31,40,55,91]. Disrupted autoregulation is often associated with a high
mortality rate and poor outcome in TBI survivors, even in minor brain injuries [96]. The
loss of cerebral vascular autoregulation increases the susceptibility of harmful secondary
effects such as hypoxia, ischemia and infarction [49,91]. Time course studies show that
within 3-5 days post-injury, over 80% of patients display an impaired autoregulation [105].
Patients who were unable to reestablish a normal autoregulation after two weeks had
unfavorable outcomes that correlated with a low GCS score, diffuse brain injury and
5

elevated ICP [105]. Changes in cerebral vascular tone and vasodilation are due at least in
part to changes in endothelial NO production [111]. The loss of vascular compensation in
response to reduced cerebral blood flow can result in regional ischemia and often results
in death. TBI can also have effects on the permeability properties of the cerebral vessels,
contributing to edema [102].
The BBB which is responsible for maintaining homeostasis between blood
circulation and the central nervous system could be compromised in TBI [102]. This
breakdown may last from several days to weeks or even years after injury occurs and the
extent of damage is directly related to the method of injury [107]. Primary damage to the
brain can lead to injured endothelial cells, leaky channels, a loss of vascular integrity and
metabolic processes [95]. BBB breakdown may occur as a result of initial injury or
secondary effects such as inflammation or metabolic disturbances. Secondary brain
damage that arises from BBB breakdown includes increased endothelial permeability
which leads to brain edema [102]. Edema that emerges from TBI can lead to fluid
accumulation in the brain and can lower perfusion of cerebral blood flow, exacerbating
detrimental effects to the TBI survivor [73,102].
Along with cerebral complications, systemic complications can also arise from TBI
such as hypertension and coagulopathy [62,118]. Many of the systemic effects seen after
TBI including increased blood pressure, cardiac output, deregulated temperature,
metabolic changes, and oxygen utilization are associated with increased levels of
circulating catecholamines [18,19,51]. Studies have shown that there is an increased
sympathetic discharge, with a large amount of catecholamines release (norepinephrine,
6

epinephrine, and dopamine) in circulation following TBI; the amounts of circulating
catecholamines present correlates with a lower GCS and more severe injury [19].
Sustained sympathetic hyperactivity peaking 1-3 weeks after injury and elevated
circulating catecholamines also predict poor outcome and increased mortality rate
[18,19,46,93]. Some individuals who sustain a TBI may develop a rare and severe
complication called a paroxysmal sympathetic hyperactivity syndrome “sympathetic
storm” [88]. Patients who suffer from sympathetic storm experience bouts of tachycardia,
hypertension, sweating and increased respiration that often occurs in waves and correlates
with an elevation of ICP [88]. The pathophysiology of sympathetic storm requires further
study, but is likely related to damage to parts of the brain that control autonomic nervous
system functions.
The sympathetic hyperactivity response from TBI can mediate cardiovascular
abnormalities and myocardial dysfunction [41,45]. These abnormalities lead to increased
blood pressure, increased pulse, tachypnea, cardiac contractility, increased troponin levels
and abnormal ECGs which may contribute to mortality [15,71,75]. In patients who endure
a head injury, 20-30% with subarachnoid hemorrhage will subsequently suffer from
cardiomyopathy, this has been referred to as neurogenic stress cardiomyopathy (NSC) [15].
Patients with NSC are at particularly high risk for potentially fatal complications such as
ventricular arrhythmias and SAH-associated cerebral vasospasm. ECG abnormalities are
observed in 75-92% of patients with intracranial bleeding [15]. Cardiovascular effects of
TBI has been described in a rat model where they reported myocardial damage from TBI;
myocytolysis, contraction band necrosis, edema formation and interstitial mononuclear cell
7

infiltration was seen in cardiac myocytes taken at different time periods following TBI
[85]. In the 24 hour trauma group, TEM analysis of cardiac myocytes showed swollen
mitochondria, dilated sarcoplasmic reticulum and large edematous areas of the cytoplasm
with significantly levels of nuclear damage [85]. Sympathetic release of catecholamines
may cause cellular stress and damage by generating ROS and forming oxidation products
[92]. ROS have also been reported in cardiac tissue in a TBI rat model produced by our
laboratory [71]. TBI affects not only the central area of impact but can also damage
peripheral organs such as the cardiovascular system resulting in cellular damage and
increased mortality.
There have been numerous clinical trials for TBI over the years including
corticosteroids [67], hypothermia [6], and progesterone [113], but few treatment options
have been shown to decrease the secondary effects of TBI. One promising area of research
is with beta adrenergic receptor antagonists (β-blockers) for treatment of TBI [4].
Adrenergic receptor antagonists may be used to try to control the sympathetic hyperactivity
that follows TBI, and can reduce the impact of sympathetic stimulation by regulating
hypertension and cardiac output [4]. In a large retrospective review, TBI patients who
happened to be on β-blockers prior to their head injury had a statistically decreased
mortality rate compared to those who were not [20]. In another study of TBI survivors
with a GCS of 5, treatment with propranolol lowered their increased metabolic expenditure
and hypertension [93]. Decreasing TBI-induced systemic hypertension could protect TBI
survivors from developing cerebral edema and improve cerebral autoregulation. However,
prospective studies of adrenergic receptor blockade for TBI are needed to determine if
8

these drugs are a suitable treatment to improve long-term outcome. Despite the extensive
literature on secondary cardiovascular effects after TBI, there are no studies focusing
specifically on effects of TBI in systemic blood vessels and particularly the endothelium.

1.4 Endothelial Vasodilatory Functions
The endothelium is a single layer of cells which lines the intraluminal space inside of
blood vessels. The endothelium has specialized tight junctions, serving as a physical barrier
between circulating blood cells and the extravascular or interstitial space. More than just
providing a physical barrier, the endothelium plays a larger role in cardiovascular
physiology; it modulates inflammatory responses, coagulation, angiogenesis, and vessel
diameter. Small resistance sized arteries with diameters less than 200 microns play a
critical role in the regulation of peripheral vascular resistance and dysregulation of vascular
tone which may contribute significantly to high blood pressure [63]. The focus of this
section will be specifically on the multiple factors released by the normal endothelium in
resistance size arteries that contribute to vasodilation and/or vasoconstriction processes.
The role of the endothelium in relaxation of blood vessels has been extensively discussed
and reviewed since its first appearance in the literature in 1980 by Furchgott [39]. It is
now recognized that there are two main pathways involved in endothelial-dependent
dilation of VSM, nitric oxide (NO) and endothelial dependent hyperpolarization (EDH).
The products of cyclooxygenase activity also dilate some vascular beds but this pathway
does not appear to play a role in dilation of resistance-sized arteries and therefore is not
reviewed in this paper.
9

1.4.1 Nitric Oxide
The involvement of NO in vascular function was first described by Furchgott and
Zawadski in 1980 and was initially called “endothelial derived relaxing factor” or EDRF
[39]. EDRF was shown to be released by the endothelium upon activation by ACh; sodium
nitroprusside (SNP), glyceryl trinitrate and NO mimic the response to ACh on the
muscarinic receptor. It was determined later that NO and EDRF were the same species,
shown by similar concentration curves and decay rates [86].
NO is a vascular protective chemical, i.e. it protects from accumulation of platelets
and plaque formation, inhibits proliferation of VSMC and decreases expression of genes
that engage in the proinflammatory response [38]. Endothelial cells synthesize NO by
endothelial nitric oxide synthase (eNOS), a Ca2+-dependent isoenzyme that may be
constitutively active, but is primarily activated by G-protein coupled receptor activation or
by shear stress induced by increased blood flow. This in turn activates eNOS through a
Ca2+-dependent mechanism [35]. eNOS converts L-arginine to L-citrulline releasing NO,
in the presence of the cofactors Tetrahydrobiopterin (BH4), oxygen, Flavin adenine
dinucleotide (FAD), and nicotinamide adenine dinucleotide phosphate (NADPH) [38]. NO
diffuses into the VSM and activates soluble guanylyl cyclase (sGC) which converts
guanosine triphosphate to cyclic guanosine monophosphate (cGMP), activating cGMPdependent protein kinase (PKG) and promoting vasodilation. PKG has multiple targets in
the VSMC. PKG general targets include 1) L-type Ca2+ channels on the plasma membrane,
which causes them to inactivate, 2) phospholamban on the sarcoplasmic reticulum (SR)
releasing its inhibition of the sarcoplasmic reticulum Ca2+ ATPase and thereby increasing
10

Ca2+ uptake from the cytosol, 3) IP3 receptors on the SR which inhibit release of Ca2+, and
4) VSM large conductance Ca2+ activated K+ channels (BKCa). These events all lead to
decreased intracellular calcium [Ca2+]i and vasodilation [23,36-38,42].

1.4.2 EDHF in the vascular endothelium
Endothelial-dependent hyperpolarization factor (EDHF) is an endothelial function
that can hyperpolarize and subsequently relax VSMC independently of NO and
prostacyclins. It involves the endothelium, and incorporates specifically endothelial Ca2+activated potassium channels (KCa) [14]. There is a variation in the nature and mechanisms
of EDHF among different vascular beds and species. EDHF can be activated by agonists
such as ACh, bradykinin, histamine or substance P causing hyperpolarization and
subsequent VSMC relaxation by decreasing cytosolic Ca2+ [68]. The EDHF-mediated
pathway in rat mesenteric arteries involve KCa, specifically: small conductance (SKCa) and
intermediate conductance (IKCa) potassium channels [14,30,62,68,77]. SKCa and IKCa
channels have a Ca2+ dependent relationship that is mediated by calmodulin, and lack
voltage sensitivity. In experimental preparations, the EDH component of ACh-induced
dilation can be evaluated using pharmacology to block KCa with charybdotoxin (BKCa and
IKCa channel blocker) and apamine (SKCa channel blocker) [68]. Of note, apamine and
iberiotoxin (BKCa channel blocker) are unable to prevent SMC hyperpolarization and AChinduced vasodilation [26]. This finding introduced confusion until it was later discovered
that while apamin and iberiotoxin together can completely abolish SKCa and BKCa channel
ion flow, neither can block IKCa channels. Charybdotoxin is thus used to block not only
11

BKCa but also IKCa channels. Together, SKCa and IKCa channels in the endothelium appear
to account for the EDH component of ACh induced vasodilation.
ACh activates muscarinic receptors on EC surface and induces a release of Ca2+
from the ER through IP3 channel activation. As a result, increased [Ca2+]i triggers SKCa
and IKCa (and also eNOS) to cause efflux of K+ out of the EC and into the myoendothelial
space. The increased concentration of K+ in the myoendothelial space activates VSMC
internally rectifying potassium channels (KIR), causing VSMC hyperpolarization and
relaxation [34].

Hyperpolarization of VSMC deactivates voltage dependent calcium

channels (VDCC), reducing Ca2+ influx and Ca2+ affinity of contractile proteins for Ca2+.
Recent results indicate that in mouse mesenteric arteries the transient receptor
potential vanalloid 4 (TRPV4) channels plays an important role in amplification of the ACh
response [103]. Hyperpolarization of the endothelium elicits TRPV4 mediated influx of
extracellular Ca2+. TRPV4 channels are the predominant extracellular Ca2+ influx pathway
involved in the vasodilation of mouse mesenteric arteries in response to ACh and
contributes approximately 75% to VSMC hyperpolarization and vasodilation [28].
Activation of few TRPV4 can lead to maximal vasodilation, in part due to the localization
of these signals at microenvironments in the myoendothelial projections. Increases of
[Ca2+]i through activation of TRPV4 also stimulate BKCa channels through ryanodine
receptor mediated Ca2+ sparks inducing vasorelaxation [28].
Endothelial cell hyperpolarization may be transferred to the VSMC via gap
junctions within these myoendothelial projections, as suggested by the fact that inhibition

12

of gap junctions by anti-connexin antibody decreases endothelial-dependent relaxation
[30]. Microdomain environments exist between SKCa and KIR, and IKCa and K+/Na+ATPases [30] and can contribute to the cooperation of KCa channels to maintain a balanced
response to shear stress, receptor agonists and electrochemical changes in the cell.
Epoxyeicosatrienoic acids (EETs) are metabolites of arachidonic acid through the
CYP enzymatic pathway and are candidates for EDHF.

ETTs are synthesized in

endothelial cells and cause hyperpolarization of VSMC through the activation of large
conductance BKCa channels [63]. Previous studies show that mouse mesenteric arterioles
rely on TRPV4-mediated activation of the EETs pathway to cause hyperpolarization and
subsequent vasodilation of resistance arteries [68]. EETs-induced vasodilation can be
inhibited by ChTx, the BKCa IKCa channel blocker, suggesting its role in the EDHF pathway
[68,80].
Hydrogen peroxide (H2O2) has also been reported to cause relaxation in vascular
tissue depending on the arterial bed. H2O2 can cause vasorelaxation in mouse mesenteric
arteries and may act as an EDHF [29]. This was shown in small mouse mesenteric artery
dilation where ACh induced hyperpolarization was abolished with incubation of catalase
in the absence of NO and COX derived pathways [78].
The contribution of EDHF to vasodilation has been extensively studied, and the
specific factors driving hyperpolarization vary in different vascular beds and diameter sizes
[30,39,62,68,99].
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1.5 Endothelial Dysfunction
Endothelial dysfunction was first described by Furchgott and Zawadski when they
observed an attenuated response to ACh after accidently rubbing the intraluminal layer of
a rabbit aorta [39]. They concluded that arterial relaxation by ACh required the presence
of endothelial cells [39]. Endothelial dysfunction has been described in a variety of
vascular related diseases such as diabetes [97], atherosclerosis [65], ischemia-reperfusion
[77], and hypertension [63]. Endothelial dysfunction is typically defined as an impaired
vasodilatory response to the muscarinic receptor agonist, ACh. Mechanisms that impair
the vasodilatory function of the endothelium include oxidative stress, impairment of NO
production (through eNOS uncoupling, increased arginase activity, or depletion of
tetrahydrabiopterin), and impairment of EDHF induced-hyperpolarization. Evidence for
each of these mechanisms in endothelial dysfunction is provided below.

1.5.1 Reactive oxygen species (ROS)
Oxidative stress and reactive oxygen species (ROS) have been common variables
in endothelial dysfunction. ROS are produced under normal conditions in the cell
through multiple enzymatic pathways such as eNOS, COX, lipoxygenase, cytochrome
P450, and NADPH oxidases [38]. Disruption to theses enzymes can lead to uncoupled
behavior resulting in an increase production of ROS [83]. NADPH oxidase has been
implicated in the production of the superoxide anion (O2-), which in turn reacts with
eNOS-derived NO to form peroxynitrite (ONOO-). ONOO- has been shown to cause
damage to endothelium through peroxidation of lipids, sulfhydryl groups, tyrosine groups
14

and guanine groups [94]. Accumulating amounts of ONOO- can uncouple eNOS by
oxidizing the Zn-thiolate in the enzyme and its cofactor tetrahydrobiopterin (BH4),
dissociating the monomers, reducing NO bioactivity and uncoupling eNOS [94]. NOS in
an uncoupled state results in an electron transfer to oxygen instead of its substrate Larginine, creating ROS [83]. Formation of ONOO- has also been shown to inhibit sGC
and inactivate prostacyclin synthase by tyrosine nitrosylation [38,94,120].
ROS, particularly O2- are believed to contribute to the pathophysiology of
hypertension by reducing the bioavailability of NO. ROS have also been implicated as a
mechanism of cerebrovascular dysfunction following TBI [6]. ROS also act on vascular
ion channels, including VSM L-type Ca channels and endothelial SK channels [3,16]. ROS
production in vascular disease can inhibit all three of the primary endothelium-dependent
vasodilator pathways (NO, EDH and prostacyclin) and tilts the balance of the endothelium
towards constriction.

1.5.2 Uncoupling of eNOS
Under pathological conditions, eNOS can act in an uncoupled mode producing
oxygen radicals that contribute to vascular diseases such as diabetes [100], hypertension
[69], atherosclerosis [101], and obesity [116]. The “uncoupled” eNOS enzyme donates
electrons to O2 instead of L-arginine, thereby producing superoxide rather than its usual
product NO. O2-. can react with NO producing peroxynitrate (ONOO-) which decreases
NO bioavailability [94]. Oxidation of the eNOS zinc-thiolate cluster by ONOO- can
uncouple eNOS [38]. In a study conducted on DOCA-salt treated hypertensive mice, ROS
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production was lowered by inhibition of NOS and knocking down nicotinamide
dinucleotide phosphate oxidases (NOX), suggesting that NOX activity produces ROS and
uncouples eNOS [69].

Figure 1 Schematic of eNOS uncoupling: Endothelial nitric oxide synthase (eNOS) can become
uncoupled through multiple factors such as a decreased amount of its cofactor BH4, increased
reactive oxygen species (ROS) and decreased amounts of its substrate L-arginine. In an uncoupled
state eNOS produces superoxide (O2-) anions which then scavenge NO, producing peroxynitrite
molecules which further uncouple the enzyme. Decreased NO can then lead to increased
vasoconstriction of the artery.

1.5.3 Role for L-Arginine and arginase in eNOS uncoupling
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L-arginine is the rate-limiting substrate in the enzymatic production of NO
through eNOS. Decreased L-arginine has been shown to contribute to eNOS uncoupling
and lead to disruption of endothelial-dependent vasodilatory function [53].

Under

pathological conditions, L-arginine supplementation has been shown to restore endothelial
dependent dilation [53].

In example, it has been demonstrated that ACh-induced

vasodilations are decreased after successive concentration response curves were performed
on the same artery [53]; this attenuated response to ACh on the 2nd and 3rd treatment is due
to the depleted stores of endothelial derived L-arginine which can be rescued by
supplementation of L-arginine [53].
Arginase is a major consumer of L-arginine and can compete for L-arginine in the
vascular endothelium, uncoupling eNOS [38].

Increased arginase activity has been

reported to contribute to endothelial dysfunction in multiple diseases such as aging [8],
ischemia–reperfusion [47], hypertension [57], atherosclerosis [115], diabetes [101] and
obesity [44]. These studies show that arginase plays an important role in regulating NO
bioavailability by competing with eNOS for L-arginine [8,44,47,57,101,115]. Arginase
inhibition can help restore dysregulated endothelial function by increasing eNOS
dependent NO production in the endothelium. A specific inhibitor of arginase, nor-NOHA,
an analog of an intermediate in the conversion from L-arginine to NO which interrupts its
Mn-cluster active site [21] has been shown to rescue dysfunctional endothelial-dependent
vasodilations in arteries [44,101].
In a diet induced obesity model, mouse aortas from high fat diet mice showed an
increase in arginase expression and a decreased expression of eNOS when compared to
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low fat diet mice aorta [44]. Inhibition of arginase by nor-NOHA restored NO levels in
the aorta of high fat diet mice [44]. Rescue of endothelial-dependent vasodilations have
also been shown in patients diagnosed with type-II diabetes mellitus and coronary artery
disease who displayed elevated levels of arginase expression [101]. Infusion with the
specific arginase inhibitor nor-NOHA restored vasodilatory responses to SNP and also
increased eNOS expression in vascular tissue [101]. Supplementation of L-arginine or
inhibition of the enzyme arginase can restore NO production in multiple disease states,
providing a potential therapeutic target for cardiovascular disease.

1.5.4 Tetrahydrobiopterin (BH4) and eNOS uncoupling
A critical determinant of eNOS activity is the availability of its cofactor (BH4)
[110]. Uncoupling of eNOS has been implicated in a number of diseases with decreased
BH4 levels, including atherosclerosis, diabetes and hypertension [24,25,101]. Deficient
BH4 availability in the endothelium has been correlated with decreased NO bioavailability,
impaired cGMP, and vasoconstriction [110]. Under conditions of limited BH4 availability
(due to oxidation or reduced formation), eNOS functions in its “uncoupled” state and
NADPH-derived electrons are added to molecular oxygen instead of L-arginine, leading to
the production of superoxide.
BH4 is a reducing agent and can become a target for oxidation during cellular
oxidative stress which in turn lowers its bioavailability. Low levels of BH4 further
contribute to an oxidative state which has been seen in high fructose-fed rats and
hypercholesterolemic patients [110], and has been linked to hypertension [69]. Oral and
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intravenous supplementation of the eNOS cofactor BH4 has been shown to lower
intracellular levels of ROS and rescue ACh-induced endothelial-dependent vasodilation in
vascular disease models [69,89,100].
Supplementation of BH4 can be performed by introducing the BH4 precursor
sepiapterin [100]. Sepiapterin can be reduced in all cells by sepiapterin reductase to 7,8dihydrobiopterin (BH2) and further by dihydrofolate reductase to form BH4 by the salvage
pathway [84]. In obese mice, BH4 supplementation with sepiapterin rescued vasodilation
in response to ACh, which was blocked by L-NAME [89].

Importantly, BH4

supplementation in animals with these diseases improves endothelial dysfunction [110].

1.5.5 EDHF
EDHF is also thought to contribute to vascular dysfunction, in rat models of
diabetes [72,112] and hypertension [64]. In a study in cultured human kidney cells, ROS
could impair EDHF hyperpolarizations by directly inhibiting the function of BKCa channels
in the VSMC by modifying a cysteine residue on BKCa channels and decreasing its
sensitivity to Ca2+ [106]. The EDHF component of vasodilation can become altered in
disease states and can lead to dysfunctional vasodilations in response to agonist
stimulation. In streptozotocin-induced diabetic rats, the role of EDHF and NO-type
relaxations in mesenteric arteries was impaired shown by

decreased ACh-induced

vasodilation in the presence of NO inhibitors and EDHF-associated channel blockers [72].
In an angiotensin infusion induced hypertension model, ACh-induced vasodilations in
mesenteric arteries resulted in attenuated responses compared to controls [64]; in that
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study, inhibition of NOS with L-NAME completely abolished ACh-dilations in
hypertensive mesenteric arteries, implying that the EDHF pathway was dysfunctional [64].

1.6 Myogenic Tone in Resistance Arteries
The myogenic response is the intrinsic ability of the VSMC to constrict or dilate in
response to changes in intravascular pressure [5,91]. The myogenic response was first
described in 1902 by Bayliss, when he noted that excised arteries would contract to
increased intramural pressure and relax under lesser pressure independent of the peripheral
nervous system [7]. Previous studies have shown that the strength of myogenic tone varies
throughout vascular beds and can also be dependent on artery size in the same vascular bed
[98].
Mechanical stretch induced by increasing intraluminal pressure activates nonselective stretch activated ion channels to elicit VSMC depolarization [98]. Changes in
membrane potential in turn activate L-type calcium (Ca2+) channels, leading to influx of
Ca2+ through these channels increasing intracellular Ca2+ ([Ca2+]i) [48]. Rising [Ca2+]i
activates myosin light chain kinase (MLCK), which can then phosphorylate myosin light
chain (MLC) allowing it to interact with ATP and bind to actin to contract VSMC. Myosin
light chain phosphatase (MLCP) removes the phosphate group from MLC inhibiting its
interaction with ATP and prevents SMC contraction. This mechanism allows for the
detachment and reattachment of myosin to actin causing vasoconstriction [98]. BKCa
channels also play a role in myogenic tone by providing a negative feedback mechanism
to oppose vasoconstriction. Increased [Ca2+]i induces Ca2+ sparks, spatiotemporal increases
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of cytosolic Ca2+ released by ryanodine receptors found on the sarcoplasmic reticulum
(SR) [12]. Ca2+ sparks activate BKCa channels and hyperpolarize the cell, inhibiting further
constriction [12].
Vascular tone can also function independently of increasing [Ca2+]i levels. The
ratio of MLCK and MLCP activity modulates MLC Ca2+ sensitivity; enzymes such as
protein kinase C (PKC) or Rho-kinase (ROK) also contribute to this mechanism.
Phosphorylation of MLCP by PKC or ROK can increase myogenic tone by inhibiting
dephosphorylation of MLC, promoting SMC contraction.
It is generally accepted that the endothelium has a role in modulating tone by
releasing basal amounts of vasodilators like NO to oppose vasoconstriction. The
involvement of the endothelium in regulating tone can vary in different species and
vascular beds [17,59,79]. For example, a study showed that rat mesenteric arteries
removed of endothelium (denuded) experienced no change in myogenic tone in response
to step-wise increase in intraluminal pressure [104]. In contrast, denuded cerebral arteries
had a profound increase in myogenic tone due to an endogenous endothelial NO production
[111]. In the mouse, denuded mesenteric arteries had enhanced myogenic response, which
was attributed to the loss of endothelial-dependent NO release [99]. The ability to develop
and maintain myogenic tone is imperative in small resistance arteries, where loss of
function or modulation is often correlated with the development of disease.

CHAPTER 2: ENDOTHELIAL-DEPENDENT DILATIONS ARE
IMPAIRED FOLLOWING TBI
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2.1 Introduction
TBI is the most frequent cause of death in children and young adults and is
increasingly recognized as a major health care problem in the United States [73].
Individuals who survive TBI may suffer from long term effects that will significantly lower
the overall quality of life. TBI is a heterogeneous disease that has variable
pathophysiological outcomes in the area of injury (the brain) and areas peripheral to injury.
Along with cerebral complications, systemic complications can also arise from
TBI. Systemic effects induced by TBI include increased blood pressure, temperature
imbalance, metabolic changes and increased oxygen utilization; all these effects can be
correlated with an increased sympathetic discharge of circulating factors such as
catecholamines [18,19,46,93]. Sympathetic hyperactivity induced by TBI has negative
effects on the cardiovascular system, coagulopathy and acute lung injury [11,85,92,118].
However, beyond cardiovascular effects, there are no data showing peripheral
damage to the vasculature caused by TBI-induced circulating factors. Arterial vasculature,
especially small resistance arteries, plays an important role in regulating peripheral
vascular resistance [60]. Increased vasoconstriction in resistance arteries may serve as a
compensatory mechanism to maintain optimal circulatory efficiency and redistribute blood
flow between and within organs to maintain normal levels of blood pressure [43].

Basal

constriction (myogenic tone) of vascular smooth muscle cells (VSMC) and relaxation
through endothelial-dependent pathways are key factors in the regulation of blood flow [4].
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The endothelium, a single layer of cells which lines the intraluminal surface of
vessels, releases vasoactive factors that contribute to vasoconstriction and vasodilation. In
resistance arteries, there are two main endothelial-dependent pathways that lead to
vasodilation: endothelial dependent hyperpolarizing factor (EDHF) and nitric oxide (NO).
Dysfunctional endothelial-dependent pathways have been implicated in multiple vascular
disease states such as diabetes, atherosclerosis, obesity, hypertension, aging, and many
more [8,24,25,44,47,57,101].

Most notably, eNOS uncoupling acts as a significant

contributor to vascular disease and impaired NO-production in the vascular endothelium.
Under pathological conditions, eNOS can become uncoupled by increased ROS production
in the vascular endothelium [38,69,94], reduced availability of its cofactor BH4
[24,25,69,101,110] or increased expression of the enzyme arginase [38,47,57].
In this study, we investigated the effects of fluid percussion-induced TBI on
endothelial-dependent vasodilatory functions in a remote systemic tissue bed (the
mesenteric microcirculation), 24 hours after injury. Based on the literature reviewed here,
we hypothesize that endothelial dysfunction, as defined by impaired endothelial-dependent
vasodilation, occurs after a TBI, due to dysregulation of either the NO or EDH pathways
of endothelial-dependent vasodilation.

2.2 Material and Methods
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2.2.1 Animals
In this study, adult male Sprague-Dawley rats (300-350 g) were used to test the
effects of TBI on mesenteric arteries. Experimental TBI was induced by a fluid percussion
injury model as previously described [71]. Briefly, a craniotomy was performed in
anesthetized rats and a bolt attached to a fluid filled column was placed between the bregma
and lambda landmarks on the skull. Brain injury was induced by releasing a pendulum to
create a pressure pulse that damages the brain. This method produces a mild and survivable
brain injury keeping the dura intact and producing astrogliosis and neurological deficits
[71]. Un-operated animals were used as controls for this study. After a 24hr recovery
period the rats were anesthetized by an intraperitoneal injection (i.p) of sodium
pentobarbital (30 mg/kg) and then euthanized by decapitation.

2.2.2 Isolation and pressurization of mesenteric arteries
After euthanasia, the small and large intestine with attached mesenteric tissue was
placed in ice cold (4 °C) physiological saline solution (PSS of the following composition:
NaCl 118.5 mM, KCl 4.7 mM, KH2PO4 1.18 mM, MgCl2 1.2 mM, NaHCO3 20 mM, CaCl2
2.5 mM, glucose 7.5 mM) and then pinned down on a sylgard plate. Fourth-order resistance
mesenteric arteries (<200 µM in diameter) were chosen for this study because they
displayed more myogenic tone compared to larger diameter mesenteric arteries (1st-3rd
order) [22].

Arteries were isolated from surrounding tissue and were mounted on

opposing small glass pipettes and secured with suture material in a small vessel chamber
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(Living Systems Instrumentation, St. Albans, VT, USA). Vessels were briefly cannulated
to remove intraluminal blood before experimentation. Arteries were pressurized using a
pressure servo system (Living Systems Instrumentation, St. Albans VT, USA) to 80 mmHg
with PSS induced by the proximal side of the mount and the distal end closed with a stop
cock. Vessels were allowed to equilibrate for 15 minutes at low pressure (10 mm Hg)
before pressure was raised to 80 mm Hg to allow vessels to develop spontaneous myogenic
contraction. Endothelium integrity was tested in each vessel with the compound NS309
(1 µM) which increases Ca2+ sensitivity to SKCa and IKCa channels. Arteries that did not
develop tone were discarded from the experimental series. The chamber was continuously
superfused with warmed PSS (37°, pH 7.4) which was bubbled with bioair (75% Nitrogen,
20% Oxygen and 5% CO2). The vessel chamber was placed on an inverted microscope
with attached CCD camera and edge detection software (Ionoptix 6.0) to monitor lumen
diameter changes. The Ca2+ channel blocker diltiazem (100 µM) in Ca2+-free PSS was
used to obtain passive diameter of vessels at the end of each experiment.

2.2.3 Assessment of endothelial dysfunction following TBI
ACh concentration response curves (CRC) were performed in mesenteric control
and TBI arteries that spontaneously developed myogenic tone. Arterial responses were
measured with increasing logarithmic concentrations of two endothelium-dependent
vasodilators ACh (1 nM to 1 µM) and bradykinin (BK) (30 pM to 300 nM). To test the role
of EDHF in mesenteric arteries following TBI, arteries were incubated with the NOS
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competitive inhibitor NG-nitro-L-Arginine (L-NNA, 100 µM) for 20-25 minutes prior to
and during agonist treatment

2.2.4 Assessment of NO contribution following TBI
To test the role of NO in ACh induced vasodilation in TBI and control groups, EDHF
antagonists apamine (30 µM) paxilline (1 µM) and charybdotoxin (200 nM)[103] were
sequentially added to the superfusing bath for 10 minutes prior to ACh addition (1 µM).
Apamine is a toxin derived from bees, and specifically inhibits SKCa channels. Paxilline
is a peptide derived from penicillium which blocks BKCa channels. Charybdotoxin is
obtained from scorpion venom and acts as a BKCa and IKCa channel blocker.
In order to obtain the contribution of KCa to myogenic tone, all blockers were added to
the bath as follows: paxilline, charybdotoxin, apamine. Decrease in lumen diameter was
calculated as a percentage of myogenic tone. ACh-induced dilation (1µM) was calculated
in the presence of all three blockers as a percentage of passive to determine NO
contribution.

2.2.5 Pressure-induced constriction (myogenic tone) and measurement of L-NNA
induced vasoconstriction.
To determine whether TBI affects myogenic tone in mesenteric arteries,
experiments were performed in pressurized arteries by increasing intraluminal pressure to
80 mmHg in control and TBI groups and quantifying % tone in comparison to maximal
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diameter achieved under passive conditions (Ca2+-free PSS and diltaiazem). To study the
role of the endothelium in myogenic response in this particular vascular bed, arteries were
endothelium denuded; endothelium was disrupted by either introducing 1-2 mL air into the
lumen of the arteries for 5 minutes or mechanical damage by carefully passing a hair
through the vessel. Removal of endothelium was determined by the lack of response to the
SKCa/IKCa channel activator NS309 (1µM). Only arteries with <15% dilation to NS309
were considered as endothelium denuded.

2.2.6 Sepiapterin Supplementation
TBI and control arteries were incubated with L-sepiapterin (1 µM), a substrate for
BH4 synthesis through the salvage pathway, separate from the de novo pathway of BH4
synthesis. Control and TBI vessels were incubated with sepiapterin for 30 minutes prior
to a CRC of ACh was performed. Furthermore, the effect of sepiapterin on myogenic tone
was also calculated in each experiment.

2.2.7 Arginase inhibition and L-Arginine supplementation
To rescue ACh induced vasodilations following TBI, mesenteric arteries from
control and TBI animals were incubated with the specific arginase inhibitor Nω-hydroxynor-Arginine (Nor-NOHA; 20 µM) or with the NOS substrate NG-amino-L-Arginine (LArginine; 100µM) for 30 minutes or until vessel diameter was stabilized; then, increasing
concentrations of ACh (1nm to 1µM) were added in the presence of Nor-NOHA or LArginine.
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2.2.8 Smooth muscle sensitivity to NO donors and contractility of vascular smooth
muscle
To test the sensitivity of VSMC to NO after TBI in mesenteric arteries, the broad
spectrum NOS inhibitor L-NNA (100 µM) was superfused for 20 minutes or until the
vessel diameter was stabilized, followed by increasing logarithmic concentrations of the
NO donor spermine NONOate (1 nM to 1µM).
SMC contractility was tested in control and TBI mesenteric arteries by introducing
logarithmic concentrations of the analog of the endoperoxide prostaglandin H2 U46619
(1nM to 1µM).

2.2.9 Drugs and Reagents
NS309 (6,7-Dichloro-1H-indole-2,3-dione 3-oxime) was purchased from Tocris
(Minneapolis, MN), 100 mM stock aliquots diluted with DMSO were prepared prior to
experimental series and were stored at -20°C.
trimethylethanaminium

chloride]

and

L-NNA

ACh [2-(Acetyloxy)-N,N,N[N5-(Nitroamidino)-L-2,5-

diaminopentanoic acid] were purchased from Sigma-Aldrich (St. Louis, MO). ACh
aliquots were diluted with Milli-Q water and stored at -20 °C and discarded after 1 month.
L-NNA was stored in powder form at room temperature; dilutions were made in 1 M HCl
and kept at room temperature. Charybdotoxin was purchased from International Peptides
and was diluted with MilliQ water. Apamine and paxilline were purchase from SigmaAldrich (Saint Louis, MO). Aliquouts were made in either DMSO or milliQ water and
were stored at -20 °C. L-sepiapterin 2-amino- 7,8-dihydro-6-(2S-hydroxy-1-oxopropyl)28

4(1H)-pteridinone was purchased from Cayman Chemical (Orlando, Florida) and stored in
powder form at -20°C. Fresh dilutions in DMSO were prepared immediately before vessel
incubation. Nor-NOHA was purchased from Cayman Chemicals (Ann Arbor, MI) and was
diluted with DMSO and stored at -20°C. L-Arginine was purchased from Sigma-Aldrich
(Saint Louis, MO), dilutions were made with milliQ water and was stored at -20°C. The
NO

donor,

Spermine

NONOate

[(Z)-1-[N-[3-aminopropyl]-N-[4-(3-

aminopropylammonio)butyl]-amino]diazen-1-ium-1,2-diolate
purchased from Cayman Chemicals (Ann Arbor, MI).

and

U-46619

were

Serial dilutions of spermine

NONOate were made with .01 M NaOH and were stored at -20°C, and U-46619 dilutions
were made in DMSO and stored at -20°C.

2.2.10 Analysis and Statistics
Myogenic tone was calculated as the percentage (%) decrease of the lumen diameter in
comparison

to

Ca2+ free

PSS

in

the

following

equation:

Tone

(%)

=

[(Dpassive−Dactive)/Dpassive]x100, where Dpassive = the (passive) lumen diameter of the artery
in Ca2+-free PSS containing the vasodilators diltiazem (100 µM) and Dactive = the (active)
lumen diameter of the artery in Ca2+-containing PSS.
% Vasodilation was calculated as the difference in diameter before and after agonist
administration normalized to maximum diameter in Ca2+ free PSS (Ddrug - Dbaseline / Dpassive
- Dbaseline)x100. % Vasoconstriction was calculated as the difference in diameter before and
after charybdotoxin, paxilline, apamine, and U46619 administration normalized to the
baseline diameter before addition of drug (Ddrug - Dbaseline / Dbaseline)x100.
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Values are represented as means ± standard error mean (SEM). Concentration‐
response curves were calculated with GraphPad Prism software (version 6.03; GraphPad
Software, Inc) to fit the Hill slope from the data (variable slope model) for each individual
experiment and then averaged to obtain the mean and SEM values. Statistical comparisons
were performed using GraphPad Prism. Because of generally small sample sizes (example
n=5 to 12), the nonparametric test Mann Whitney was used for comparison between 2
groups. We also used repeated measures analysis of variance (ANOVA) for the comparison
of multiple groups at different concentrations. Statistical significance was considered at the
level of P<0.05.

2.3. Results

2.3.1 Agonist-induced vasodilations in mesenteric arteries from control and TBI
animals
Measurement of the extent of vasodilation induced by the muscarinic-receptor
agonist ACh is the standard assay for endothelial dysfunction in pressurized arteries. To
assess endothelial function following TBI, ACh concentration-response curves (1 nM to 1
µM) were performed in fourth order mesenteric arteries isolated from control and TBI
animals and constricted with myogenic tone (Figure 2A). ACh-induced vasorelaxation
was significantly attenuated in arteries from TBI rats compared to control (Figure 2C)
suggesting a compromised endothelial-dependent vasorelaxation following TBI (n= 6,
P<0.0001, Two-way ANOVA). Maximal dilation to ACh (1 µM) was severely diminished
in TBI arteries compared to controls (59 ± 9% of passive diameter, n=6 vs 100 ± 1% of
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passive diameter, n=6)). LogEC50 values for control and TBI arteries were -7.4 ± 0.09
(n=6) vs -7.2 ± .43 (n=6), respectively, demonstrating a shift in the PD2 values in TBI.
Arteries from TBI animals could not maximally dilate to ACh, Emax was impaired.
In order to confirm the finding of endothelial dysfunction, and not simply
downregulation of muscarinic receptors, we also performed concentration response curves
with a different endothelial-dependent vasodilator bradykinin, which acts through
bradykinin receptors. We performed a concentration-response curve of bradykinin (30 pM
to 300 nM) in control and TBI arteries. Bradykinin (BK) induced vasodilations were also
attenuated following TBI (n=5, Two-way ANOVA, P<0.0001). With a shift in the
sensitivity to BK LogEC50 values for control and TBI arteries were -9.0 ± 0.07 (n=5) vs 8.1 ± 0.04 (n=5), respectively. Arteries obtained from TBI animals dilated maximally to
BK.

These data confirm that endothelial-dependent vasodilations are impaired in

mesenteric arteries from TBI rats.

2.3.2 EDHF contribution to ACh-induced vasodilation following TBI
To determine which endothelial derived pathway was causing a lack of vasodilation
in response to ACh, we investigated the role of both EDHF and NO in ACh-mediated
vasodilation. We evaluated the EDHF contribution by blocking the NO pathway with a
broad NOS competitive inhibitor, L-NNA (100 µM) prior to and during ACh concentration
challenge (1 nM to 1 µM) in both control and TBI arteries. In the presence of L-NNA (100
µM), ACh-induced dilations were attenuated in controls (1 µM ACh, 58 ± 12% of passive
diameter, n=7, P<0.0001, Two-way ANOVA) but not in the TBI group (1 µM ACh, 63 ±
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8% of passive diameter, n=6, Two-way ANOVA, n.s.) (Figure 2D), suggesting the EDHF
component is intact in mesenteric arteries following TBI. These data indicate that the
contribution of NO to ACh-induced dilations is blunted after TBI, suggesting either a lack
of NO production or efficacy in mesenteric arteries obtained from TBI rats.
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Figure 2: Endothelial dysfunction was assessed in arteries from TBI rats by an endothelial
dependent agonist ACh. Representative trace of arteries from control and TBI animals (A) ; arteries were
allowed to develop myogenic tone at 80 mmHg, and were then subjected to stepwise increases of the
muscarinic receptor agonist acetylcholine (ACh). (B) ACh concentration curves were performed in the
presence of NOS inhibitor L-NNA (100 mM) dilations. (C) Summary data of ACh response curve in control
and TBI groups. (D) Summary data of ACh response curve in the presence of L-NNA in control and TBI.
(Two-way ANOVA, P<0.0001).
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Figure 3: Bradykinin induced vasodilations are attenuated in mesenteric arteries following TBI.
Concentration response curves were performed in pressurized arteries from control and TBI rats in a pressure
myograph system (A)(Two way ANOVA p<0.0001). (B) Response increased concentrations of bradykinin
in the presence of the NOS inhibitor L-NNA. Vasodilation (% vasodilation) was quantified as the measured
vessel diameter normalized to maximal relaxation of the same artery in Ca2+-free buffer

2.3.3 NO contribution to ACh-induced vasodilation following TBI
To further investigate the roles of endothelial dependent vasodilations in control
and TBI arteries, the EDH pathway was inhibited with the pharmacological blockers:
apamine (300 nM), charybdotoxin (200 nM), and paxilline (1 µM) (Figure 4A-B). AChinduced dilation (1 µM) in control arteries (Figure 3A) were reduced, but not blocked (17
± 3% of passive diameter, n=10), implying that in control groups the NO pathway is intact
(Figure 3A). However, the dilation to ACh (1 µM) in the presence of these blockers was
partially inhibited in TBI arteries (9 ± 3% of passive diameter, n=8, Mann-Whitney test,
P<0.05) compared to controls (Figure 4C). The effect of SKCa, IKCa and BKCa channel
blockade on basal tone was also tested in TBI and control arteries. We found no difference
between groups (Figure 4D). Overall this indicates that in the absence of EDHF
component, the NO associated pathway is unable to dilate arteries following a TBI.
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Figure 4: Endothelial dysfunction following TBI involves impairment in NO-component of
vasodilation: Representative trace showing control (A) and TBI (B) arteries in the presence of
pharmacological blockers of EDHF vasodilatory pathways. Arteries were incubated in the presence of
apamin (300 nM), charybdotoxin (200 nM) and paxilline (1 µM) prior to addition of ACh (1 µM).
Vasodilation (% vasodilation) was quantified as the measured vessel diameter normalized to maximal
relaxation of the same artery in Ca2+-free buffer. (C) Summary data show that TBI arteries displayed a
significant diminution in the NO component of ACh-induced dilation compared to controls (Mann-Whitney
test, P <0.05). (D) Summary of basal activity of EDHF related channels are not different between groups.
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2.3.4 NO release or production is decreased in TBI mesenteric arteries
The basal production of NO in mesenteric arteries was measured indirectly by
measuring the constriction induced by the NOS competitive inhibitor L-NNA (100 µM)
(Figure 4). L-NNA induced vasoconstriction was attenuated in arteries from TBI rats (3 ±
2% change in baseline, n=9) compared to controls (8 ± 1% change in baseline, n=12)
(Mann-Whitney test, P<0.05) (Figure 5C), indicating a decreased basal NO production in
TBI arteries.
Pressure-induced constriction (myogenic tone) was also measured in arteries from
control and TBI animals (Figure 5D). Arteries from TBI rats showed enhanced myogenic
tone compared to controls at 80 mmHg, respectively (40 ± 9 % tone, n=6 vs 27 ± 2% tone,
n=10). Denuded mesenteric arteries from control rats displayed an enhanced myogenic
tone similar to arteries from TBI rats (42 ± 7% tone, n=6 vs 39 ± 3% tone, n=5, n.s.)
indicating that in this vascular bed, a tonic release of NO counterbalances the myogenic
response. Endothelium denudation had no effect on myogenic tone development within
the TBI group. Inhibition of NO production with L-NNA (100 µM) normalized the level
of tone between groups (33 ± 3% tone, n=17 vs 35 ± 2%, n=12, n.s.) (Figure 5D).
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Figure 5: Decreased NO bioavailability and increased myogenic tone in TBI arteries: Representative
trace of control (A) and TBI (B) arteries exposed to the nitric oxide synthase inhibitor L-NNA (100 nM), the
resulting vasoconstriction was quantified as the luminal diameter normalized to the baseline diameter of the
same vessel (% change in baseline). (C) Summary data of % constriction in response to L-NNA in control
and TBI arteries (T-test, P<0.05). (D) Summary data of myogenic tone in TBI and control arteries in intact
and denuded vessels, and in the presence of L-NNA.
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2.3.5 Effect of L-Sepiapterin supplementation on ACh-induced dilation
Previous studies have reported that deficient NO production in vascular disease has
been linked to eNOS uncoupling by oxidation of the NOS cofactor BH4 by ROS. To test
whether the lack of cofactor contributes to a decreased eNOS activity and uncoupling of
eNOS, we added an exogenous substrate for BH4 synthesis, L-sepiapterin (1 µM)[89].
Concentration-response curves of ACh (1 nM to 1 µM) were performed in control and TBI
vessels in the presence of L-sepiapterin (1µM) (Figure 6). L-sepiapterin supplementation
rescued the maximal dilation to ACh (1 µM) in TBI arteries (91 ± 1% of passive diameter,
n=5 vs 86 ± 6% of passive diameter n=5) (Figure 5B). However, L-sepiapterin was not
able to rescue the entire ACh concentration response curve in TBI. L-sepiapterin (1 µM)
incubation also had an effect on ACh induced vasodilations in control vessels, attenuating
ACh induced vasodilations from 30nm-1 µM (Figure 6A), suggesting that addition of BH4
into control arteries disrupts normal vasodilatory function. The effect of sepiapterin on
myogenic tone on TBI arteries was tested. We found no difference in tone between TBI
and control vessels (32 ± 1% of tone vs 32 ± 2% of tone) (Figure 6C). Sepiapterin was
able to restore arterial tone in arteries from TBI animals compared to controls. Overall,
Sepiapterin partially restored ACh vasodilations (Emax) and fully restored myogenic tone
in arteries obtained from TBI animals.
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Figure 6: The BH4 precursor L-sepiapterin partially restored endothelial dependent dilations in TBI
arteries: Sepiapterin (1 µM) was incubated in control (A) and TBI (B) vessels before and during ACh
response curves at 80mmHg. (C) Summary data of ACh CRC in the presence of sepiapterin. (D)
Measurement of the effect of sepiapterin on myogenic tone in Control and TBI arteries. % Tone was
quantified as the measured vessel diameter normalized to maximal relaxation of the same artery in Ca2+-free
buffer.
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2.3.6 L-Arginine supplementation and arginase inhibition rescues ACh-induced
vasodilations in arteries from TBI rats
The partial rescue of BH4 synthesis through exogenous supplementation of the
substrate sepiapterin lead us to change our focus from the cofactor and look at the eNOS
substrate L-arginine. Control and TBI arteries were incubated with L-arginine (100 μM)
before and during an ACh concentration response curve (1 nm to 1 µM). Supplementation
with L-arginine rescued ACh-induced dilations in TBI arteries compared to TBI arteries
without supplementation (1 µM ACh; 98 ±1% of passive vs 59 ±9% of passive) (Figure
7D).
Previous studies have shown that the enzyme arginase competes with eNOS for Larginine and therefore may contribute to endothelial dysfunction [8,38,47,101,115].
Therefore, we tested ACh-induced dilations in the presence of the arginase inhibitor norNOHA (20 μM) in control (Figure 7A) and TBI (Figure 7B) arteries. Incubation with norNOHA rescued ACh-induced in TBI compared to TBI arteries without rescue (1 µM ACh;
98 ±1% of passive vs 59 ±9% of passive). These data indicate that increases of arginase
activity and associated reduction in cellular L-arginine levels in the vascular endothelium
reduces NO levels because of reduced eNOS substrate (L-arginine) availability.
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Figure 7: Supplementation of L-arginine and inhibition of arginase restores endothelial function in
mesenteric arteries following TBI: ACh induced concentration response curve in the presence of the
specific inhibitor of arginase Nor-NOHA (20 µM) (Nω-hydroxy-nor-Arginine) in control (A) and TBI (B)
arteries. (C) Summary data showing ACh CRC in the presence of Nor-NOHA, (D) Control and Mesenteric
arteries subjected to ACh CRC in the presence of L-arginine. Dotted lines represent control arteries
previously shown in Figure 1.
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2.3.7 Vascular smooth muscle sensitivity to NO and contractility
To determine if the vascular smooth muscle sensitivity to NO was altered following
TBI, VSMC sensitivity was tested by performing a concentration-response curve with the
NO-donor spermine-NONOate (1 nM to 1 µM) in the presence of L-NNA (100 µM) to
prevent endogenous NO production. Spermine NONOate elicited endothelial-independent
vasodilations which were not significantly different between groups (n=5-6, Two-way
ANOVA, p> .05) (Figure 8A).
To investigate if VSMC constriction responses were changed in TBI mesenteric
arteries, contractility was tested by performing concentration response curves with the
agonist U-46619 (3 nM to 1 µM) (Figure 8B) at low pressures to avoid the contribution of
myogenic tone (40 mm Hg). U-46619 elicited VSMC constrictions were were similar
between groups (n=4, Two-way ANOVA, p>.05)
An alternate hypothesis for impaired NO production would be decreased eNOS
expression. To further investigate whether TBI affects eNOS expression, eNOS mRNA
levels were measured in isolated fourth order mesenteric arteries from control and TBI rats.
Quantitative-PCR (qPCR) showed that there was no difference of eNOS mRNA levels
between groups (Figure 8C).
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Figure 8: Smooth muscle sensitivity to NO and functional contractility is not altered in TBI vessels:
(A) Smooth muscle sensitivity to NO was determined using the NO donor Sperimine NONOate in the
presence of L-NNA in control and TBI arteries. (B) Smooth muscle contractility was determined by
performing U-46619 CRC in control and TBI arteries. (C) mRNA expression was measured in Control and
TBI arteries, there was no significant difference.
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2.4 Discussion
This is the first study conducted to address the effects of TBI on areas remote from
the site of injury. This study begins to address how TBI has a peripheral effect on
vasculature in addition to the well-documented cerebral effect. We hypothesized that TBI
causes profound changes in mesenteric arteries resulting in a loss of endothelial-dependent
vasodilation 24 hours after brain injury.

We were able to demonstrate endothelial

dysfunction in TBI mesenteric arteries by performing concentration response curves for
two different endothelial-dependent vasodilators, the muscarinic agonist ACh and BK. We
found that endothelial-dependent dilations to both agonists were impaired in fourth-order
mesenteric arteries 24 hours after TBI and that the NO pathway is impaired following TBI;
however the EDHF pathway remained intact, providing the predominant endotheliumdependent vasodilatory mechanism in arteries obtained from TBI animals. We also studied
whether eNOS uncoupling could be responsible for the lack of eNOS-mediated dilations
following TBI which has been shown in other animal models of diabetes [100],
hypertension [69] and obesity [116]. Supplementation with the BH4 precursor sepiapterin
partially rescued ACh-induced vasodilations (1 µM) and restored myogenic tone in arteries
from TBI rats. Furthermore, we found that arginase inhibition with nor-NOHA and
supplementation with L-Arginine rescued ACh-induced vasodilations in mesenteric
arteries following TBI.
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Our functional assay of ACh-induced dilations demonstrated that endothelialdependent vasodilations were impaired in fourth-order mesenteric arteries 24 hours after
TBI (Figure 2). When the contribution of NO was abolished by L-NNA, ACh-induced
vasodilations were partially inhibited in control mesenteric arteries, indicating that AChinduced vasodilation involves both NO and EDHF pathways (Figure 6). However, NOS
inhibition had no effect in TBI arteries, suggesting the lack of NO bioavailability and
contribution to ACh-induced dilations following TBI. The remaining dilation to ACh in
the presence of L-NNA (100 µM) shows the EDHF component of ACh-induced dilations,
which implicates the contribution of KCa channels (SK and IK) also present in the vascular
endothelium which are activated by a rise in intracellular cytosolic Ca2+ upon agonist
stimulation [108].

As Figure 1 shows, ACh-induced dilations measured in TBI rats

mimicked those of control in the presence of L-NNA (100 µM) suggesting that the EDHF
component is the only vasodilatory pathway that remains intact following TBI in this
vascular bed. Vasoconstriction in response to apamine, charybdotoxin, and paxilline in
control and TBI arteries was similar, further demonstrating that the EDHF pathway is intact
following TBI (Figure 4). From these data we can conclude that the EDHF pathway is
intact in mesenteric arteries following TBI.
In control arteries, EDHF represents ~50% of the maximal ACh-induced
endothelial-dependent vasodilation (Figure 2C). This finding contradicts previous studies
that suggest small resistance arteries rely mostly on EDHF (~75%) for vasodilation
[28,54,68,97]; these differences in EDHF contribution could be due to different species or
to the arterial diameter elected for study.

In other models of disease such as diabetes,
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disruptions of the EDHF pathway have been reported [72,106,112]. In this regard, our data
do not support the findings from Leo et al, where they showed that both the NO- and
EDHF-mediated relaxations were significantly diminished in mesenteric arteries from
streptozotocin-induced diabetes animal model [72]. This can be attributed to the difference
in disease model (diabetic vs TBI) or possibly chronicity of the disease pathway (TBI acute
onset and diabetes long term). However, a study conducted on mesenteric arteries in an
ischemia-reperfusion model, where they showed NOS inhibition attenuated ACh-response
by ~50%, does support our findings that the NO-component contributes more to AChinduced dilations in rat mesenteric arteries than previously mentioned [77].
We also used a different agonist to explore whether or not the endothelial
dysfunction seen after TBI is unique to the muscarinic receptor ACh. Bradykinin (BK), an
agonist of the B2 receptor which is also located in the vascular endothelium, induced
vasodilation in control and mesenteric arteries (Figure 3). BK-induced vasodilations were
significantly attenuated in TBI arteries without altering Emax (Figure 3). This may be
indicative of a different mechanism of endothelial-dependent vasodilation in response to
bradykinin or that the ACh muscarinic receptor is dysfunctional in TBI mesenteric arteries.
A study done in rat mesenteric arteries in vivo showed that the NOS inhibitor L-NAME
plus indomethacin did not inhibit BK-induced blood flow [87], implying that BK dilates
vessels mainly through the EDHF pathway. Contradicting this, previous studies have
proven that BK-induced dilation in mesenteric arteries functions through both the NO and
EDHF pathway and can be attenuated by the NOS inhibition [68]. However, the inability
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of vasculature to dilate in the presence of the agonist ACh or BK has been a reference for
the loss of vascular integrity specifically for endothelial-dependent dysfunction.
When the contribution of EDHF was inhibited with apamin, charybdotoxin and
paxilline, relaxations to ACh (1 µM) were significantly decreased in TBI compared to
normal arteries, further suggesting that the contribution of NO was impaired by brain injury
(Figure 3). To measure basal NO production, the constriction to L-NNA was measured in
arteries from control and TBI animals. Control arteries expectedly constricted ~20%
(compared to tone) in response to L-NNA which is consistent with previous studies
[61,72,81]. However, constriction to L-NNA in arteries taken from TBI animals was
significantly decreased compared to controls (Figure 6C) indicating that basal level of NO
production is decreased in mesenteric arteries from TBI rats demonstrating an impaired
NO pathway in systemic circulation following TBI. In comparison, in cerebral arteries NO
production is increased following TBI compared to controls [111]. This might be a
compensatory mechanism of traumatic brain injury found centrally and not peripherally.
Vascular tone at 80 mm Hg was also measured in mesenteric arteries from control
and TBI groups. TBI arteries displayed an enhanced myogenic tone compared to controls
(Figure 4D). Denuded TBI arteries had no difference in myogenic tone compared to intact
TBI, however, control denuded arteries displayed an enhanced myogenic tone similar to
that of TBI arteries. Inhibition of NOS with L-NNA in control arteries diminished the NO
component and was similar to the myogenic response of TBI arteries, demonstrating that
increased myogenic tone in TBI rats is due to an impaired function of eNOS. Although
the role of endothelial vasoactive factors in modulating myogenic tone has been
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controversial, in this study we have correlated the lack of NO production with an increase
of myogenic tone. This increase in basal constriction was not due to altered sensitivity to
NO (Figure 7A) or to increase of VSMC contractility (Figure 7B) since both remained
intact in TBI mesenteric arteries.
After confirming endothelial dysfunction in TBI mesenteric arteries, we studied
whether a decreased concentration of the essential eNOS cofactor BH4 promoted eNOS
uncoupling, resulting in a lack of NO-derived vasodilations in response to ACh.
Supplementation with sepiapterin, an intermediate in the salvage pathway of BH4
synthesis, showed partial rescue to ACh-induced vasodilation at the maximal concentration
of 1 µM (Figure 6C) and restored myogenic basal tone compared to controls (Figure 6D)
but was unable to rescue concentrations of 1 nM-300nM of ACh. Sepiapterin rescue at
only 1 µM ACh could imply that the muscarinic receptor sensitivity to ACh is impaired in
mesenteric arteries following TBI. Sepiapterin rescue of maximal dilation is consistent
with the obesity model of vascular disease, where 3rd order mesenteric arteries were
rescued from attenuated vasodilations to ACh at 1 μM [89]. However, a concentration
response curve was not performed in this study so we were unable to compare our results
obtained at lower concentrations of ACh.
Recent data suggest that the ratio of BH4:BH2 may be a more important
determinant of eNOS function than the absolute concentration of BH4 [56,109,110]. In an
oxidative environment BH4 can be oxidized to BH2 which has a higher binding affinity to
eNOS than BH4. Although BH4 oxidation was not investigated in this study, increased
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concentrations of BH2 may explain why supplementation with sepiapterin was not able to
rescue eNOS function in TBI arteries.

On the other hand, high concentrations of

sepiapterin could also uncouple eNOS leading to generation of superoxide O2−. Recently,
it has been shown that BH2 and sepiapterin inhibit NOS in vitro by displacing the pre-bound
BH4 with >80% efficiency [58]. BH2 and sepiapterin are metabolites that accumulate in
patients with variants of BH4 deficiency, and it has been suggested that they may potentiate
the superoxide formation during the uncoupled reaction of NOS [9,119].
The BH4 precursor sepiapterin was unable to rescue the concentration-response
curve of ACh which lead us to investigate whether the eNOS substrate, L-arginine, could
explain compromised ACh-induced vasodilation following TBI. We discovered that
exogenous supplementation with the NOS substrate L-arginine (100 μM) did rescue AChinduced vasodilations in TBI arteries (Figure 7D). Since arginase and eNOS share the
same substrate, an increased arginase activity or expression could decrease L-arginine
bioavailability.

In this regard, several studies have shown the role of arginase in

endothelial dysfunction and eNOS uncoupling under different physiological and
pathological states [8,44,47,57,90,101]. Incubation with the specific inhibitor of arginase
nor-NOHA (20 µM) rescued ACh-induced dilations in our model of TBI (Figure 7A-C).
Further studies measuring total arginase expression using western blot analysis will be
necessary to determine if increased arginase is responsible for uncoupling eNOS and
promoting endothelial dysfunction following TBI. Despite the selectivity of arginase
inhibitors, it has been reported that nor-NOHA can potentially inhibit eNOS in mesenteric
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arteries; supplementation of L-arginine + nor-NOHA however rescued ACh-induced
vasodilation in control mesenteric arteries [53].
In our study, we did not find increased eNOS expression in mesenteric arteries
following TBI (Figure 8). Similar findings were seen in an ischemia reperfusion model
where eNOS protein level expression measured in mesenteric arteries was also not
increased. Also, in an obesity model, eNOS expression was not different between control
and disease groups, however, eNOS activation measured by phosphorylation was
decreased, contributing to impaired endothelial-dependent dilations [116]. In mesenteric
arteries from a rat model of obesity it was reported that there was no difference in total
eNOS expression; however, eNOS dimerization suggested that eNOS was acting in a
monomeric state which was responsible for uncoupled behavior [72]. Although we
determined that eNOS expression is not altered following TBI, it is also possible that the
activity of eNOS is altered by post-translational modification or uncoupling and undimerization.
Finally, because there has been some controversy about the role of endothelial
vasoactive factors in regulating myogenic tone, we also tested the vascular smooth muscle
function to rule out VSMC dysfunction as mechanisms of impaired vasodilation (Figure
7). We tested both vasodilation in response to NO and contractility in response to the
thromboxane agonist U-46619, and found no differences in VSMC function at 24 hours
after TBI compared to controls. Thus, the increase in vascular tone after TBI is not due to
change in sensitivity to NO (Figure 8A) or altered contractility of VSMC (Figure 8B) but
due to the dysfunctional endothelium.
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The vascular effect seen remote from the site of injury might suggest the
contribution of circulating factors such as histones, polyphosphates or other unidentified
factors. Recently, they have been implicated in TBI [66] and other pathological states like
sepsis [114] or lung-associated injury [1]. Whether they cause endothelial damage to
resistance-sized arteries remains unclear. In summary, this study demonstrates that fluid
percussion induce TBI causes profound vascular systemic damage to mesenteric arteries,
leading to a dysfunctional TBI induces a release of circulating factors into the systemic
circulation, causing a dysfunctional endothelial-dependent vasodilation in mesenteric
arteries and increased arginase activity (Figure 9). Arginase in turn competes with eNOS
for L-arginine; consumption of L-arginine by arginase starves eNOS causing a loss of
eNOS function. This in turn diminishes NO-production in the vascular endothelium
resulting in a compromised endothelial-dependent vasodilation to agonist stimulation
(ACh and BK) and increased myogenic tone due to a decreased basal NO production.

2.5 Conclusions and Future Directions
Traumatic injury to brain tissue causes release of circulating factors normally
sequestered from the circulation, along with massive catecholamine release and
elevations in ROS. Several studies have shown that TBI can lead to cardiovascular
pathology, but to our knowledge, there are no studies focusing specifically on the
vascular endothelium after TBI. This is an important area for research, because
endothelial dysfunction could explain the hypertension, coagulopathy and impaired
barrier functions of pulmonary and cerebral vessels, often seen after trauma.
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Overall, this study demonstrates 24 hours after a traumatic brain injury, systemic
resistance vessels show signs of endothelial dysfunction, manifest as impaired
endothelial-dependent vasodilation. This appears to be due to an increased activity or
expression of arginase activity in the endothelium. This increase in arginase activity or
expression subsequently leads to competition for L-arginine, limiting the ability of eNOS
to produce of NO (Figure 9). These results have important clinical implications.
Resistance sized arteries which are extremely important in regulating blood pressure,
circulating blood volume, and the production of anti-coagulant factors. This damage to
vascular endothelium could contribute to the dysfunctional coagulation factors seen in
patients after trauma. Thus, our data suggests that arginase inhibition may be a potential
therapeutic target to rescue endothelial function in TBI patients.
Future studies can be performed to determine if the activity of eNOS is altered by
post-translational modification through Western blot analysis can determine if eNOS is
acting in a coupled or uncoupled form, or if its active form (phosphorylated) is being
expressed. Also, it is unknown if the arginase enzyme has an increased protein
expression in the endothelium or if its activity is increased by post-translational
modification. This can be later determined with western blot analysis of protein levels
and phosphorylization of arginase. The isoform of arginase can be determined by
immunohistochemistry of fixed sections of endothelium. Further studies using the slit
open artery preparation (Figure 10) incubated with the fluorescent indicator DAF-2 DA
of 4th order mesenteric arteries can help distinguish if the production of NO is altered
following TBI. To test if there is an increased production of ROS in the mesenteric
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vascular endothelium, further studies using immunohistochemistry in control and TBI
arteries could be performed.

Figure 9: Schematic for endothelial dysfunction following TBI: Traumatic Brain Injury causes a release
of circulating factors into the systemic system causing an increase of arginase activity or expression in
vascular endothelium. Increases of arginase introduces a competitive environment for L-arginine, starving
eNOS for L-arginine and causing eNOS uncoupling. eNOS can no longer produce NO, this leads to a
decrease of basal and agonist induced NO production and an increase of myogenic tone.
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2.6 Limitations
We acknowledge the limitations of this study. One possible limitation is the 24
hour time point of this study. We recognize that systemic pathophysiological outcomes
of TBI can last for up to two weeks after injury. However, we chose one time point to
ensure consistency of injury and outcome. Second, only male Sprague Dawley rats were
investigated in this study and the findings cannot be generalized to the female rat
population due to the neuroprotective mechanisms in the female rat [2,27]. Third, we did
not assess the prostacyclin pathway of endothelial-dependent dilations due to various
accounts that have shown that the addition of the cyclooxygenase (COX) inhibitors has
no effect on ACh-induced vasodilations in control arteries [89,97,112]. Specifically in
rat mesenteric arteries, the contribution of the prostacyclin pathway in endothelial
mediated vasodilation is controversial. However, other models of disease have shown a
tendency of an increased cyclooxygenase derived products such as PGI2 when there is an
inhibited or impaired NO contribution [68,72]. Fourth, we did not explore the levels of
ROS because it was beyond the scope of this project. It is apparent that ROS may play a
role in mesenteric artery dilation following TBI. ROS have been a common denominator
when studying endothelial dysfunction in vascular disease and is a hallmark of
endothelial dysfunction and eNOS uncoupling.
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CHAPTER 3: SUPPLEMENTARY METHODS AND RESULTS

3.1 Slit open preparations
To assess basal production of NO in control animals, mesenteric arteries were
dissected from surrounding tissue and were pinned down and slit open on a sylgard plate
with the endothelium facing upwards (Figure 10) [111]. The artery was incubated with the
NO fluorescent indicator assay 4.5-diaminofluorescein (DAF-2 DA; 10 µM) for 1 hr at
32°C in the dark and was then imaged with a spinning disk confocal microscope at 30
frames/sec as previously described [111]. The vessel was superfused with oxygenated PSS
and warmed to 37°C for 15 minutes before recordings to allow deesterfication of the
fluorescent indicator. Fluorescence intensity and pseudocolor images were analyzed with
a custom software (Sparkan, Dr. Bonev, University of Vermont).

Unfortunately an

increase of NO production in the presence of the muscarinic receptor ACh was not easily
detected in control arteries. We speculated that the reason for this may be that NO release
in mesenteric arteries due to ACh was too small to detect with the DAF-2 DA which has a
detection limit of 2-5 nM. The viability of the preparation may have been compromised
during the slitting open and pinning; over stretching the vessel may have damaged or torn
endothelial cells, making imaging extremely difficult.
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Figure 10: NO production in the endothelium from slit open arteries assessed by DAF-2 fluorescence:
en face preparation of 3rd order control mesenteric arteries showing NO staining indexed by DAF-2. Addition
of NO donor Spermine (10 µM) slightly increased the NO production in endothelium.

3.2 Cryostat sections
Fourth order mesenteric arteries were dissected and were briefly cannulated to
remove intraluminal blood before freezing. Arteries were placed in OCT freezing medium
and then frozen in 2-methyl-butane chilled with dry ice for 30 sec. Frozen sections (100
uM) were made with a cryostat; the sections were then incubated with 10 μM DAF-2 DA
for 30 minutes at room temperature (Figure 11). Negative controls were not incubated with
DAF-DA, control and TBI arteries were incubated with DAF-2 DA and were imaged,
control and TBI arteries were challenged with ACh (100 μM) and imaged. These data were
not incorporated due to the difficulty of viewing the endothelium in the arterial cross
sections. Although overall NO in the artery seems to be elevated in the controls compared
to TBI, we decided not to continue with this technique due to the lack of proper
characterization of NO (DAF-2 DA) staining in the endothelial layer.
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Figure 11: NO production in fresh (unfixed) frozen sections of mesenteric arteries: NO production
indexed by the fluorescent indicator DAF-2 DA in 100 µm sections of mesenteric arteries in control (A) and
TBI (D) arteries (n=1). Application of ACh (100 µM) on both groups (B & E), Negative Controls showed
autofluorescence in the absence of DAF-2 DA (C & F)
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